That brand is more than just a logo - it’s ... as B2C firms do. Some pharmaceutical brands are even experimenting with influencers, including a recent campaign from Gilead Science.

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $95.00. The company’s shares closed last Friday at $82.81.

Gilead will pay Genesis $35 million for three targets. There could also be further payments if more targets are identified, along with milestone payments. Genesis previously collaborated with ...

Chris Schott has given his Buy rating due to a combination of factors revolving around Gilead Sciences’ drug, lenacapavir, and its potential impact on the market. Schott points out the ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

Sometimes, a delay is caused by a patent review, so the PTO will compensate a pharmaceutical company by extending the life of the patent by the number of days caused by the delay. Conversely ...